A recent study has shown that administration of FGF19 causes skeletal muscle hypertrophy, by stimulating the phosphorylation of ERK1/2 and P70S6K1, and ameliorates obesity-induced skeletal muscle atrophy in mice (37). The gene discussed is RPS6KB1; the disease is obesity due to melanocortin 4 receptor deficiency.